Evidence map›Paper›PMID 30934587›Full record

ArticleInternational journal of molecular sciences2019

Plasma Rich in Growth Factors (PRGF) Disrupt the Blood-Brain Barrier Integrity and Elevate Amyloid Pathology in the Brains of 5XFAD Mice.

Quoc-Viet Duong, Margia L Kintzing, William E Kintzing, Ihab M Abdallah, Andrew D Brannen, Amal Kaddoumi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Evaluation of the Efficacy of Xyloglucan, Pea Protein andInternational journal of molecular sciences · 2023
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Quoc-Viet DuongDepartment of Basic Pharmaceutical Sciences, School of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201, USA. duongqa@warhawks.ulm.edu.ORCID 0000-0002-4562-0831
Margia L KintzingHealth Science Center, LSU Department of Family Medicine, Shreveport, LA 71103, USA. plkintzing@att.net.
William E KintzingHealth Science Center, LSU Department of Family Medicine, Shreveport, LA 71103, USA. Wkintz@lsuhsc.edu.
Ihab M AbdallahDepartment of Drug Discovery and Development, Harrison School of Pharmacy, Pharmacy Research Building, Auburn University, Auburn, AL 36849, USA. iza0012@tigermail.auburn.edu.
Andrew D BrannenDepartment of Drug Discovery and Development, Harrison School of Pharmacy, Pharmacy Research Building, Auburn University, Auburn, AL 36849, USA. adb0009@auburn.edu.ORCID 0000-0002-1318-2304
Amal KaddoumiDepartment of Drug Discovery and Development, Harrison School of Pharmacy, Pharmacy Research Building, Auburn University, Auburn, AL 36849, USA. kaddoumi@auburn.edu.ORCID 0000-0001-9792-7766
Auburn University · USLouisiana State University Health Sciences Center Shreveport · USUniversity of Louisiana at Monroe · US

Funding

Targeting cerebrovascular endothelial cells as a therapeutic approach for amyloid pathogenesisR15NS091934 · NINDS · UNIVERSITY OF LOUISIANA AT MONROE · PI KHALIL KADDOUMI, AMAL F · 2015 to 2015
$420k
National Institute of Neurological Disorders and Stroke R15NS091934
6 · The paper itself

Abstract

Alzheimer's disease (AD) is the most common neurodegenerative disorder affecting 5.4 million people in the United States. Currently approved pharmacologic interventions for AD are limited to symptomatic improvement, not affecting the underlying pathology. Therefore, the search for novel therapeutic strategies is ongoing. A hallmark of AD is the compromised blood-brain barrier (BBB); thus, developing drugs that target the BBB to enhance its integrity and function could be a novel approach to prevent and/or treat AD. Previous evidence has shown the beneficial effects of growth factors in the treatment of AD pathology. Based on reported positive results obtained with the product Endoret

Indexed as

AmyloidAmyloid beta-PeptidesAnimalsAstrocytesBiomarkersBlood-Brain BarrierCytokinesDisease Models, AnimalDisks Large Homolog 4 ProteinInflammation MediatorsIntercellular Signaling Peptides and ProteinsIodine RadioisotopesMice, TransgenicPlasmaProtein TransportVascular Endothelial Growth Factor AAmyloidAmyloid beta-PeptidesBiomarkersCytokinesDisks Large Homolog 4 ProteinDlg4 protein, mouseInflammation MediatorsIntercellular Signaling Peptides and ProteinsIodine-125Iodine RadioisotopesVascular Endothelial Growth Factor Aamyloid-β clearanceblood-brain barrierbrain endothelial cellsplasma rich growth factorsvascular endothelial growth factor

Identifiers

PMID30934587
PMCPMC6471393
OpenAlexW2922631458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.